Will telling 23andMe to delete personal data protect your genetic information? Not entirely
There's always a chance the data doesn't get erased — but consumers should ask 23andMe to delete their information anyway, ...
23andMe files for bankruptcy, putting its hoard of personal health information at risk
23andme says it owns the aggregated genetic data of its customers, meaning it can sell it to the highest bidder ...
Undark Magazine17h
In Genetics, a Tense Coexistence of Mainstream and Fringe Views
In an era of open data, genome-wide association studies have become entangled with efforts to prove Black inferiority.
Public Broadcasting Service (PBS)1d
What happens to DNA data of millions as 23andMe files bankruptcy?
The bankruptcy of 23andMe is raising concerns about the future of its DNA information. Once a pioneer in the genetic testing industry, the company faced backlash after hackers leaked user data in 2023 ...
23andMe has filed for bankruptcy. What does this mean for your DNA data privacy?
Me has filed for bankruptcy, prompting people who've used the service and sent in DNA samples to be analyzed to wonder what ...
As 23andMe goes into bankruptcy, here's why you should consider deleting DNA data
The DNA of millions of people could be up for sale, as testing company 23andme filed for bankruptcy this week. Here’s how to ...
New AI model predicts gene variants' effects on specific diseases
Cedars-Sinai investigators have developed a novel artificial intelligence (AI) model, named DYNA, that accurately ...
Intrigue on MSN1d
Genetics Vs Lifestyle: If Living Healthy is So Important to Longevity, Why Do Some Unhealthy People Live so Long?
Agnes Fenton of Englewood, New Jersey, celebrated her 110th birthday in 2015. For about 70 years, she followed a daily ritual ...
Pooled prime editing: Mass screening of genetic variants can clarify disease risk
Researchers at the Francis Crick Institute have demonstrated that a genetic method called "pooled prime editing" can screen ...
Nature5d
Medical genetics articles from across Nature Portfolio
Despite their immense potential, gene and cell therapies that target rare diseases are at risk of market withdrawal, owing to several challenges. The authors describe these hurdles and call for ...